Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting — Chronic Lymphocytic Leukemia Edition

Featuring an interview with Dr John Allan, including the following topics: •      Update on key studies of acalabrutinib in the front-line setting (0:00) •      Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) •      Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) •       Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) •      Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) •      Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) •      Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) •      Emerging data with novel Bcl-2 inhibitors (1:11:26) •      Evolving data with subcutaneous epcoritamab for patients with Richter’s transformation and CLL (1:14:37) CME information and select publications